Oxford Biomedica

Leader in lentiviral vector technology, the predominant transfection technology for the rapidly growing CAR-T therapy space

Oxford Biomedica

Leader in lentiviral vector technology, the predominant transfection technology for the rapidly growing CAR-T therapy space

  • Partner with world leading pharma companies to develop lentivirus enabled therapies, such as CAR-Ts
  • Key input provider for Kymriah, the first FDA-approved CAR-T therapy 
  • Supports therapies from pre-clinical to commercialisation, including producing lentivirus under GMP conditions
  • Recently supported Oxford University and AstraZeneca on the development of the COVID vaccine, which uses an adenovirus vector 
  • Attractive business model of recurring services and bioprocessing revenues, as well as milestones and royalties on products that use their proprietary IP

Key facts

  1. Sales £85m
  2. Employees c.650
  3. Industry Life Sciences & Healthcare
  4. Headquarters UK & Ireland
  5. Geographic Footprint Europe
  6. Website www.oxb.com
  7. Investment Date February 2021
  8. Fund VIP III Cortex

Investment Facts

Oxford Biomedica

Leader in lentiviral vector technology, the predominant transfection technology for the rapidly growing CAR-T therapy space

Key facts

  1. Sales £85m
  2. Employees c.650
  3. Industry Life Sciences & Healthcare
  4. Headquarters UK & Ireland
  5. Geographic Footprint Europe
  6. Website www.oxb.com
  7. Investment Date February 2021
  8. Fund VIP III Cortex
  • Partner with world leading pharma companies to develop lentivirus enabled therapies, such as CAR-Ts
  • Key input provider for Kymriah, the first FDA-approved CAR-T therapy 
  • Supports therapies from pre-clinical to commercialisation, including producing lentivirus under GMP conditions
  • Recently supported Oxford University and AstraZeneca on the development of the COVID vaccine, which uses an adenovirus vector 
  • Attractive business model of recurring services and bioprocessing revenues, as well as milestones and royalties on products that use their proprietary IP

Back